Latest article
Bayer’s Finerenone Meets Major Endpoint in Section III FIGARO-DKD Cardiovascular Outcomes Research in Sufferers...
WHIPPANY, NJ - (BUSINESS WIRE) - Bayer's phase III cardiovascular outcome study FIGARO-DKD evaluating the efficacy...
